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TransmetallationMutations in the metalloprotein Cu,Zn-superoxide dismutase (SOD1) cause approximately 20% of familial cases
of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease for which effective therapeutics do not
yet exist. Transgenic rodent models based on over-expression of mutant SOD1 have been developed and these
have provided opportunity to test new therapeutic strategies and to study themechanisms of mutant SOD1 tox-
icity. Although the mechanisms of mutant SOD1 toxicity are yet to be fully elucidated, incorrect or incomplete
metallation of SOD1 confers abnormal folding, aggregation and biochemical properties, and improving the
metallation state of SOD1 provides a viable therapeutic option. The therapeutic effects of delivering copper
(Cu) tomutant SOD1have beendemonstrated recently. The aim of the current studywas to determine if delivery
of zinc (Zn) to SOD1was also therapeutic. To investigate this, SOD1G37Rmicewere treated with themetal com-
plex diacetyl-bis(4-methylthiosemicarbazonato)zincII [ZnII(atsm)]. Treatment resulted in an improvement in lo-
comotor function and survival of themice. However, biochemical analysis of spinal cord tissue collected from the
mice revealed that the treatment did not increase overall Zn levels in the spinal cord nor the Zn content of SOD1.
In contrast, overall levels of Cu in the spinal cordwere elevated in the ZnII(atsm)-treated SOD1G37Rmice and the
Cu content of SOD1 was also elevated. Further experiments demonstrated transmetallation of ZnII(atsm) in the
presence of Cu to form the Cu-analogue CuII(atsm), indicating that the observed therapeutic effects for ZnII(atsm)
in SOD1G37R mice may in fact be due to in vivo transmetallation and subsequent delivery of Cu.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative dis-
order that involves the loss of functional motor neurons in the spinal
cord resulting in progressive paralysis and death within 3–5 years of
diagnosis (Pratt et al., 2012). Incomplete understanding of the patho-
genesis of ALS has contributed to the absence of effective therapeutics
for the disease: Riluzole is currently the only approved drug for the
treatment of ALS but its efﬁcacy is marginal with only a modest exten-
sion in survival (Bensimon et al., 1994; Miller et al., 1996). Pre-clinical
development of new treatment options is needed, not only to identify
compounds with potential for successful clinical translation, but also
to advance our understanding of ALS pathogenesis.
The majority of ALS cases arise sporadically with no known cause.
However, 10% of cases are familial (Pratt et al., 2012) and of those,, The University of Melbourne,
).
ect.com).
. This is an open access article underapproximately 20% are due to mutations in the gene for Cu,Zn superox-
ide dismutase (SOD1) (Andersen et al., 2003), a ubiquitous enzyme
responsible for scavenging superoxide radicals (Perry et al., 2010).
Transgenic rodent models that over-express mutant forms of SOD1
develop ALS like symptoms and despite legitimate caveats associated
with all transgenic over-expression animal models of human disease,
these mutant SOD1 animals remain the current gold-standard for
pre-clinical development of new ALS therapeutics (Gurney et al.,
1994; Wong et al., 1995).
The mechanisms by which SOD1 mutations cause ALS remain
unclear, but accumulating data indicate a signiﬁcant role for the bio-
metals zinc (Zn) and copper (Cu) (Elliott, 2001). ALS-causingmutations
alter the metal binding capacity of SOD1 (Rodriguez et al., 2002;
Hayward et al., 2002) and this can result in misfolding of the protein
and its aggregation (Ding and Dokholyan, 2008; Bourassa et al., 2014).
Further to this, previous studies have suggested that Zn-deﬁcient
SOD1 is a signiﬁcant toxic form of SOD1: Zn-deﬁcient mutant SOD1
and Zn-deﬁcientwild-type SOD1 are both toxic tomotor neurons in cul-
ture due to their capacity to promote peroxynitrite mediated damage
(Crow et al., 1997; Estevez, 1999). It has also been shown that loss ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the redox-active CuII ion in the active site becoming more accessible to
intracellular reductants leading to reduction to CuI (Roberts et al.,
2007). Under these conditions CuI promotes the formation of superox-
ide from molecular oxygen which is then able to react with nitric
oxide to form peroxynitrite. Signiﬁcantly, formation of a SOD1heterodi-
mer containing one Zn-deﬁcient monomer and one fully metallated
monomer stabilises the Zn-deﬁcient form and increases its toxicity
(Sahawneh et al., 2010).
Previous reports investigating the metallation status of different
mutant forms of SOD1 concluded that incorrect metallation of mutant
SOD1 is not involved in aggregation or toxicity due to the high levels
of metal per dimer in the soluble form of the protein (Lelie et al.,
2011). However, the techniques used were not able to directly detect
the metallation status of SOD1 and metallation status was inferred
from the amount of metal per dimer. Recently developed techniques
allow us to directly detect the metallation status of SOD1 allowing
a more accurate investigation of the role of metals in SOD1 toxicity
(Rhoads et al., 2011; Roberts et al., 2014).
Treatment with the metal complex diacetyl-bis(4-
methylthiosemicarbazonato)copperII [CuII(atsm)] is therapeutic
in the SOD1G93A (Soon et al., 2011) and SOD1G37R (McAllum
et al., 2013) mouse models of ALS. In the SOD1G37R mice there
is a large pool of metal-deﬁcient mutant SOD1 in the spinal
cord tissue and the majority of this is due to Cu-deﬁcient SOD1
(Roberts et al., 2014). Treatment with CuII(atsm) increases Cu
in the spinal cord and decreases the Cu-deﬁcient pool of SOD1
by delivering Cu to the mutant protein, indicating that Cu-
deﬁcient SOD1 may play a role in ALS-like pathogenesis in
these mice (Roberts et al., 2014). Treatment with CuII(atsm)
also increased the Zn content of SOD1 and this was proposed to
be due to stabilisation of the protein (Roberts et al., 2014). How-
ever, given that treatment with CuII(atsm) increased the Cu con-
tent and the Zn content of mutant SOD1 in the spinal cords of
SOD1G37R mice (Roberts et al., 2014), it remained unclear
whether the strong therapeutic outcomes for the CuII(atsm)
treatment (McAllum et al., 2013) were due to its effects on the
Cu-deﬁcient or Zn-deﬁcient SOD1. In an attempt to delineate
the importance of Cu versus Zn delivery in the therapeutic activ-
ity of CuII(atsm), mice in the present study were treated with the
CuII(atsm) analogue, ZnII(atsm). Locomotor function and survival
of the mice were assessed to determine therapeutic effects and
the metal content of spinal cord tissue from treated mice was
analysed using hyphenated HPLC–ICP-MS.
Methods
Animals
SOD1G37R mice purchased from the Jackson Laboratory were
established and maintained as a colony by breeding with C57BL/6
non-transgenic mice. The genotype of these mice was determined
using the REDExtract-N-Amp™ Tissue PCR kit (Sigma) to prepare DNA
from tail snips taken from the mice at the age of weaning. Primers and
cycle times usedwere those taken from the Jackson Laboratory website.
Mice were housed in standard boxes with sawdust and shredded paper
for beddingwith 2–5 animals per box. All procedureswere approved by
an institutional animal ethics committee (University of Melbourne).
Preparation and administration of ZnII(atsm)
ZnII(atsm) was prepared as previously described (Cowley et al.,
2002, 2005). For administration to mice, ZnII(atsm) was prepared
daily by suspending in standard suspension vehicle [SSV: 0.9% (w/v)
NaCl, 0.5% (w/v) Na-carboxymethylcellulose (medium viscosity), 0.5%
(w/v) benzyl alcohol and 0.4% (w/v) Tween-80] at a concentrationof 7.5 mg mL−1. Transgenic mice and non-transgenic littermates were
treated daily by oral gavage with 30 mg kg−1 ZnII(atsm) or an equiva-
lent volume of vehicle. Approximately equal numbers of male and fe-
male mice were included in each treatment group. Treatment of
SOD1G37R mice with ZnII(atsm) was performed concurrently with
treatments performed for one of our previous studies (McAllum et al.,
2013). Survival and rotarod data presented herein for vehicle-treated
mice has been published previously (McAllum et al., 2013) and is
reproduced with permission from the publisher Informa Healthcare.
None of the biochemical analyses in the present study, including data
from vehicle treated mice, has been published previously.
Assessment of locomotor function
The locomotor function of the mice was assessed twice a week
beginning at 12 weeks of age using the rotarod task. The rotarod was
set to accelerate from 4 to 40 rpm over 180 s. The time at which the
mouse failed the taskwas recorded as latency to fall. During each testing
session, every mouse was tested twice and the highest latency to fall
score was recorded. Researchers administering the task were blind to
the genotypes and treatments of the mice.
Determining disease end-stage
End-stage was deﬁned as the age at which mice had a rotarod score
of less than 3 s and were unable to right themselves in less than 30 s
when place on their side due to hind limb paralysis. In accordance
with ethical procedures, mice were killed at disease end-stage by
cervical dislocation. Researchers determining end-stage were blind to
treatment group.
Tissue collection and preparation for analysis
A cohort of treatedmicewas reserved for tissue collection at 24weeks
of age. Mice were anesthetised with ketamine (120 mg kg−1) and
xylazine (16 mg kg−1) prepared in phosphate buffered saline (PBS).
Once fully anesthetised themice were perfused with PBS containing pro-
tease inhibitors, phosphatase inhibitor cocktail and heparin. Spinal cords
were collected, frozen on dry ice immediately and then stored at−80 °C
until prepared for analysis. Prior to ICP-MS and LC–ICP-MS analyses, spi-
nal cord tissuewas prepared by homogenising in TBS containing protease
inhibitors and soluble and insolublematerial separated by centrifugation.
Soluble material was used for both ICP-MS and LC–ICP-MS analyses and
insoluble material was further processed according to published proto-
cols (Maynard et al., 2006) before analysis by ICP-MS.
ICP-MS and LC–ICP-MS
Inductively coupled plasma mass spectrometry (ICP-MS) and
hyphenated size exclusion chromatography, inductively coupled
plasma mass spectrometry (LC–ICP-MS) were performed as previously
described (Roberts et al., 2014;Maynard et al., 2006)with the following
exceptions for LC–ICP-MS: a micro mist nebuliser was used instead of a
Mira Mist; He gas ﬂow was 3.3 mL min−1; spinal cord samples were
homogenised in TBS containing protease inhibitors and 80 μg total pro-
teinwas injected onto the column from the TBS solublematerial. Elution
of SOD1 from the column was determined using puriﬁed bovine SOD1
(Sigma Aldrich). Bovine SOD1 eluted at 399 s with a Ve/Vo of 1.5.
Transmetallation in CuCl2
ZnII(atsm) solubilised in DMSO was mixed with increasing concen-
trations of CuCl2 (CuCl2·2H2O in DMSO) ranging from 0.2 to 1 Cu
molar equivalents. After thorough mixing and 1 min incubation at
ambient temperature, absorbance spectra from λ = 400–600 nm
were measured using a UV/Vis spectrometer.
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All statistics were performed using GraphPad Prism software.
Rotarod data were analysed using a two-way repeated measures
ANOVA with Bonferroni post test and survival data were analysed
using the Log-rank (Mantel–Cox) test, a commonly used non-
parametric test for survival analysis which assumes proportional
hazard. All other data sets were analysed using the unpaired t-test to
compare the mean of datasets.Fig. 1. The effect of ZnII(atsm) treatment on locomotor function and survival in SOD1G37R
mice. A. The locomotor function of SOD1G37Rmice treatedwith 30mg kg−1 ZnII(atsm) or
vehiclewas assessedusing the rotarod assay and recorded as latency to fall (n=11 and 14
respectively; p b 0.0001). Due to mice reaching end-stage, the number of mice per treat-
ment group begins to decline at 164 days for the vehicle-treated group and 201 days for
the ZnII(atsm)-treated group. The dotted line indicates the age atwhich tissuewas collect-
ed from a second cohort of mice for additional analyses in Fig. 2. B. The locomotor function
of non-transgenic C57BL/6 mice treated with ZnII(atsm) or vehicle was assessed using the
rotarod assay and recorded as latency to fall (n = 16 and 21, respectively). C. Kaplan–
Meier survival curves for the same mice used in Fig. 1A. (p b 0.0001). Error bars in A and
B represent SEM. Note, all data for vehicle treated mice have previously been published
(McAllum et al., 2013) and are reproduced with permission from the publisher Informa
Healthcare.Results and discussion
Locomotive function of vehicle treated SOD1G37R mice began to
decline at approximately 150 days of age (Fig. 1A). This progressive de-
cline was signiﬁcantly delayed by treatment with ZnII(atsm) but the
magnitude of the delay was less than that seen when the SOD1G37R
mice were treated with CuII(atsm) at the same dose (McAllum et al.,
2013). As previously reported for the CuII(atsm) treatment, ZnII(atsm)
did not have any stimulatory effect on the locomotive function of non-
transgenic littermates (Fig. 1B). In line with rotarod performance, sur-
vival of the SOD1G37R mice was signiﬁcantly extended by treating
with ZnII(atsm): mean survival for the vehicle treated SOD1G37R mice
was 196 days compared to 210 days for the ZnII(atsm) treated mice
(Fig. 1C). This equates to a 7% increase in survival for the ZnII(atsm)
treated SOD1G37R mice, signiﬁcantly less than the 18.2% extension in
survival observed for SOD1G37R mice treated CuII(atsm) at the same
dose (McAllum et al., 2013). The survival effect for ZnII(atsm) adminis-
tered at 30 mg kg−1 is comparable to the 8.4% extension observed
in SOD1G37R mice treated with CuII(atsm) at 10 mg kg−1 (McAllum
et al., 2013).
Previous analyses have shown SOD1G37R mice have a signiﬁcant
pool of Cu-deﬁcient SOD1 (~58 μM) in the spinal cord and that delivery
of Cu by CuII(atsm) to SOD1 decreases the abundance of this species
(Roberts et al., 2014). A signiﬁcant pool of Zn-deﬁcient SOD1 also exists
within the spinal cords of these mice but this is present at a lower con-
centration (~1.2 μM) than the Cu-deﬁcient SOD1 (Roberts et al., 2014).
Given that this in vivo concentration of Zn-deﬁcient SOD1 is higher than
the concentration required to kill motor neurons in vitro (Crow et al.,
1997), it is possible that the relatively small pool of Zn-deﬁcient SOD1
contributes tomotor neuron death or dysfunction in vivo. We therefore
assessedwhether the therapeutic activity observed for ZnII(atsm) in the
SOD1G37R mice involved modulation of the Zn-deﬁcient pool of SOD1
(Fig. 1). Analysis of tissues by ICP-MS and LC–ICP-MS revealed that
treating with ZnII(atsm) did not signiﬁcantly alter the Zn content of
the spinal cords nor the Zn content of the SOD1 in the spinal cords of
the SOD1G37R mice however there was a trend towards an increase
in Zn in both the soluble material and insoluble material (Figs. 2A and
B). Despite the absence of any signiﬁcant change in Zn levels, the
ZnII(atsm) treatment did signiﬁcantly increase the Cu content of the
spinal cord from 2.32 ± 0.91 to 6.03 ± 0.63 μg g−1 tissue wet weight
in the solublematerial and from2.21±0.22 to 4.91±0.35 μg g−1 tissue
wet weight in the insolublematerial (Fig. 2A). This is reﬂected in the Cu
content of the SOD1 in the spinal cordwhich increased from0.16±0.01
to 0.23 ± 0.02 μg g−1 tissue wet weight in the ZnII(atsm) treated mice
(Fig. 2B). Consequently, the Cu:Zn ratio for spinal cord SOD1 also in-
creased from 0.43 ± 0.008 in the vehicle treated SOD1G37R mice to
0.54 ± 0.015 in the ZnII(atsm) treated mice (Fig. 2C). The Cu:Zn ratio
in the vehicle-treated mice is consistent with that reported by others
employing a similar method (Lelie et al., 2011). While this result was
unexpected for mice treated with a Zn-compound, it lends support to
the potential for Cu-deﬁcient SOD1 to be a contributor to the ALS-like
phenotype ofmutant SOD1mice and the therapeutic efﬁcacy of increas-
ing levels of bioavailable Cu in the spinal cord (Roberts et al., 2014).
Presuming that the ALS-like phenotype of the SOD1G37Rmice is driven
solely by the presence of mutant SOD1, ZnII(atsm) improves thelocomotive function and survival of the mice by increasing the Cu
content of the mutant SOD1 (Fig. 2).
The relative chemical properties of ZnII(atsm) and CuII(atsm) pro-
vide some insight to explain how treatment with ZnII(atsm) can have
a greater effect on the Cu content of spinal cord SOD1 than it does
on the Zn content of the protein. Speciﬁcally, ZnII(atsm) and similar
ZnII-complexes of bis(thiosemicarbazones) are less stable than their
Cu equivalents and readily transmetallate in the presence of available
Cu (Barnard et al., 2008; Donnelly et al., 2008) which can inﬂuence
the cellular activity of these compounds in vitro and in vivo (Donnelly
et al., 2008; Petering, 1974). If this occurs with ZnII(atsm) in the
Fig. 2. The effect of ZnII(atsm) treatment on the total Cu and Zn concentration and the Cu and Zn content of SOD1 in SOD1G37Rmouse spinal cord tissue. A. The concentration of Cu and Zn
in the soluble and insoluble material from spinal cord of vehicle and ZnII(atsm) treated mice was determined by ICP-MS and presented as μg metal g−1 tissue wet weight. B. Cu and Zn
content of the SOD1 containing size-exclusion fraction determined by LC–ICP-MS and calculated as μg metalg−1 tissue wet weight. C. Data collected in Fig. 2B were used to calculate
the molar Cu/Zn ratio of SOD1. Bovine SOD1 is shown as a control. Solid lines represent the mean and error bars, SEM. * p b 0.05, ** p b 0.001, *** p b 0.0001.
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tively delivers a lower dose of CuII(atsm) due to partial transmetallation
once the compound enters the digestive and/or circulatory system. To
test this directly ZnII(atsm)was incubatedwith CuCl2 and the distinct ab-
sorption spectra from ZnII(atsm) and CuII(atsm) monitored using UV/Vis
spectrometry. Increasing concentrations of CuCl2 caused a shift in the ab-
sorbance spectra away from ZnII(atsm) and towards CuII(atsm) (Fig. 3).
This result is consistent with previous studies which have demonstrated
complete transmetallation of ZnII(atsm) and other ZnII complexes of
bis(thiosemicarbazones) when in the presence of available equimolar
Cu (Holland et al., 2007; Matsumoto et al., 1992; Saji et al., 1992). Given
this high susceptibility to transmetallation and the likelihood that orally
administered ZnII(atsm) encounters available Cu (e.g. Cu from food in
the digestive system), in vivo transmetallation of ZnII(atsm) appears to
support the observed changes to total Cu (Fig. 2A) and SOD1-associated
Cu (Figs. 2B, C) in the spinal cords of ZnII(atsm) treated SOD1G37Rmice.
Transmetallation affecting the therapeutic activity of ZnII(atsm)
in the SOD1G37R mice is analogous to results from an earlier
study which examined the closely related compounds 3-ethoxy-2-
oxobutyraldehyde bis(thiosemicarbazone) (H2kts) and 3-ethoxy-2-
oxobutyraldehyde bis(N4-dimethylthiosemicarbazone) (H2ktsm) and
their respective Cu- and Zn-complexes (Petering, 1974). When investi-
gating the anti-cancer cytotoxic activity of these compounds, the
metal-free ligands and their Cu and Zn complexes demonstrated clear
cytotoxic activity, but metal-free ligands and Zn-complexes were onlyFig. 3. Transmetallation of ZnII(atsm) to form CuII(atsm). Absorbance spectra from 400 to
600 nm of ZnII(atsm) mixed with increasing concentrations of CuCl2 from 0.2 to 1 Cu
molar equivalents. The transition of blue to red indicates the increase in CuCl2 concentra-
tion and the formation of CuII(atsm).active when administered with a Cu supplement (Petering, 1974). Fur-
ther investigation found that ZnII(kts) and ZnII(ktsm) both readily
transmetallated in the presence of available Cu to form CuII(kts) and
CuII(ktsm), respectively. Transmetallation did not occur in plasma
alone indicating a lack of available Cu and it was rationalised that
the in vivo cytotoxic activity of the metal-free ligands and the
Zn-complexes was dependent upon transmetallation utilising dietary
Cu (Petering, 1974). Given the chemical similarities that these com-
pounds sharewith ZnII(atsm), it is plausible that the same phenomenon
may be occurring in the ZnII(atsm) treated SOD1G37R mice.
Data presented in this study show that orally treating ALS model
SOD1G37R mice with ZnII(atsm) improves their locomotive function
and extends survival, albeit to a lesser extent than the same dose of
CuII(atsm) as demonstrated in a previous study (Roberts et al., 2014).
This may be because rectifying potential Zn deﬁciencies in these mice
has less of an impact on their phenotype than rectifying Cu deﬁciencies
via strategies that increase Cu bio-availability (Roberts et al., 2014), or
because the therapeutic activity for ZnII(atsm) in these mice is depen-
dent upon transmetallation to CuII(atsm) and that transmetallation in
these mice was incomplete. Data in Figs. 2 and 3 provide stronger sup-
port for the latter of these two possibilities, particularly the data that
show treatment with ZnII(atsm) improved the Cu content of mutant
SOD1 in the spinal cord tissue but did not change Zn content of the
protein. However, the toxicity of Zn-deﬁcient SOD1 to motor neurons
has been demonstrated (Estevez, 1999), and decreasing levels of
Zn-deﬁcient SOD1 therefore has clear therapeutic potential. The possi-
bility still remains that ZnII(atsm) itself is therapeutic. The amount of di-
etary available Cu would not be enough to transmetallate the entire
dose of ZnII(atsm) so some ZnII(atsm) may still make it into the central
nervous system. Once there, ZnII(atsm) as a complex may be having
some unknown therapeutic effect independent of Zn delivery. If true ef-
ﬂux of excess Zn from the cell is presumably sufﬁciently rapid to mask
detectable changes to the total pool of Zn in the spinal cords of the
ZnII(atsm) treatedmice. Transmetallation of ZnII(atsm) has confounded
our attempt to investigate the potential to treat ALS-like symptoms in
SOD1G37Rmice by speciﬁcally delivering bio-available Zn. Compounds
less amenable to transmetallation may be required to delineate these
two metals in mutant SOD1 models of ALS, in both their role in patho-
genesis and their opportunity for therapeutic intervention.Conﬂict of interest statement
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